The Lymphoma Research Group was established in October 2012 as an emerging group within the Institute. Its research focuses on understanding the molecular mechanisms involved in the development, progression, and response to treatment of lymphomas, with a special emphasis on follicular lymphoma and aggressive B lymphomas.

The group analyzes samples from patients using genomic, epigenetic, and transcriptomic techniques, both in tumor tissue and in liquid biopsy. These studies are complemented by analysis of the tumor microenvironment, spatial transcriptomics, and functional assays in cell lines and three-dimensional models. The integration of these data allows studying how the characteristics of tumor cells and their environment interact, identifying resistance mechanisms, and searching for biomarkers useful for diagnosis, prognosis, and the selection of treatments.

The group’s research has a translational character. It addresses some of the questions relevant to patients and combines the analysis of clinical samples with experimental models to assess the functional significance of the findings. Current lines of research include the study of the progression and transformation of follicular lymphoma, the molecular characterization of diffuse large B-cell lymphoma, and the development of liquid biopsy-based tools for patient stratification and predictive therapy response.

The group brings together researchers from different disciplines and works in close collaboration with clinical professionals, hospital services, technological platforms, and other national and international research groups. This collaboration facilitates access to clinical samples and data, as well as the application of various technologies to the study of lymphomas.

In recent years, the group has obtained competitive funding to study the microenvironment of follicular lymphoma (PI23/01587) and develop a multiomic signature in liquid biopsy for aggressive B lymphomas (CPP2023-010616). It is also involved in initiatives related to methylation biomarkers in diffuse large B cell lymphoma (PI25/00553), advanced therapy networks, research infrastructure, and European collaboration in cancer. These projects continue the group’s previous work in functional models and precision medicine in aggressive B lymphomas.

Training is another essential part of its activity. The group directs doctoral theses and final-year degree and master's degree projects, and welcomes students, research staff in training, and residents for stays and research rotations.